Standard Biotools Inc. (LAB)

Name: Standard Biotools Inc. (LAB) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name STANDARD BIOTOOLS INC. · CIK 0001162194 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Standard Biotools Inc. reported revenue of $85.33M. Revenue fell 6.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $84.60M.

Key ratios (year ended 2025-12-31)

49.9%

Gross margin

-129.2%

Operating margin

-87.8%

Net margin

-17.7%

Return on year-end equity

-6.2%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-05

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$84.60M	$85.33M	$91.01M	$106.34M	$97.95M	$130.58M	$138.14M	$117.24M	$112.96M	$101.94M	$104.45M
Cost of Revenue	$41.89M	$42.79M	$46.12M	$55.89M	$60.90M	n/a	n/a	$52.96M	$51.31M	$49.95M	$46.01M
Gross Profit	$42.71M	$42.54M	$44.88M	$50.45M	$37.05M	n/a	n/a	$64.28M	$61.65M	$51.98M	$58.44M
R&D Expense	$18.42M	$25.99M	$28.83M	$25.95M	$37.38M	$37.94M	$36.46M	$31.64M	$30.03M	$30.83M	$38.41M
Operating Income	-$95.47M	-$110.25M	-$127.48M	-$76.60M	-$116.20M	-$67.46M	-$51.04M	-$51.84M	-$48.16M	-$58.36M	-$73.19M
Depreciation & Amortization	$5.49M	$9.26M	$12.52M	$3.98M	$3.50M	$3.65M	$4.01M	$4.61M	$5.37M	$7.41M	$6.74M
EBITDA	-$89.97M	-$100.99M	-$114.97M	-$72.62M	-$112.71M	-$63.81M	-$47.02M	-$47.23M	-$42.79M	-$50.95M	-$66.45M
Net Income	$84.91M	-$74.90M	-$138.88M	-$74.66M	-$190.10M	-$59.24M	-$53.02M	-$64.79M	-$59.01M	-$60.53M	-$75.98M
EPS (Diluted)	n/a	-$0.20	-$0.52	-$0.94	-$2.43	-$0.78	-$0.74	-$0.97	n/a	n/a	n/a
Total Assets	$627.22M	$567.75M	$612.35M	$323.07M	$390.31M	$275.21M	$324.76M	$264.81M	$303.65M	$287.35M	$306.39M
Total Liabilities	$87.25M	$143.46M	$140.62M	$159.87M	$160.52M	$180.62M	$185.71M	$111.20M	$231.53M	$256.42M	$253.16M
Long-Term Debt	n/a	n/a	$299.0K	$63.51M	$64.89M	n/a	n/a	n/a	n/a	n/a	n/a
Shareholders' Equity	$539.97M	$424.29M	$471.72M	-$148.05M	-$81.47M	$94.60M	$139.05M	$153.61M	$72.12M	$30.93M	$53.23M
Cash & Equivalents	$270.03M	$120.86M	$166.73M	$51.70M	$81.31M	$28.45M	$68.52M	$21.66M	$95.40M	$58.06M	$35.05M
Operating Cash Flow	-$80.30M	-$74.34M	-$143.45M	-$43.29M	-$89.37M	-$44.06M	-$15.42M	-$35.21M	-$25.20M	-$24.10M	-$39.14M
Capital Expenditures	$2.28M	$8.30M	$8.36M	$2.83M	$3.83M	$13.26M	$12.72M	$2.53M	$372.0K	$1.57M	$5.07M
Free Cash Flow	-$82.58M	-$82.65M	-$151.81M	-$46.12M	-$93.19M	-$57.33M	-$28.13M	-$37.74M	-$25.57M	-$25.66M	-$44.20M
Share Repurchases	n/a	$0	$40.49M	$5.41M	$563.0K	$0	n/a	n/a	n/a	n/a	n/a
Shares Outstanding	392.12M	386.38M	377.53M	80.23M	79.48M	76.92M	74.54M	69.96M	49.34M	38.79M	29.21M
Weighted Average Diluted Shares	n/a	381.62M	353.25M	79.16M	78.31M	75.79M	72.04M	66.78M	n/a	n/a	n/a
EPS (Basic)	n/a	-$0.20	-$0.52	-$0.94	-$2.43	-$0.78	-$0.74	-$0.97	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView